Enliven Therapeutics, Inc.

NASDAQ:ELVN

Biotechnology

Healthcare
$44.89 -0.27%

-$0.12 today

Market cap
$3.30B
Beta
0.40
P/E (TTM)
-28.4
EPS (TTM)
-$1.57
52W Low $14.79High $48.53

Volume 0.75M

Average 1.35M

ELVN Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Enliven Therapeutics, Inc.NASDAQ: ELVN

Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q3 FY2026 selling, general & admin of $8.02M rose 16.7% year over year, behind the +35.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 2.3% from the prior quarter. Over 3 fiscal years it compounded at +63.3% a year.

Context

  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 4 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +42.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$8.02M-2.3% QoQ
Last fiscal yearDec 2025
$33.8M+42.2% YoY
LTMSep 2026
$36.41M+35.2% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.7%-100.0%-116.7 pp
1 year+42.2%-100.0%-142.2 pp
3-year CAGR+63.3%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
33.8M USD
Year-over-year change
+42.2%
4-year CAGR
+67.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ELVN compares with its peers on the latest reported figures

  • ELVN's LTM Sep 2026 selling, general & admin of $36.41M is the 8th highest of the 11 companies compared; the peer median is $105.43M.
  • Its year-over-year change of +35.2% is the 3rd highest of 11, against a peer median of +17.1%.
  • Over three fiscal years its annual growth of +63.3% compares with a peer median of +17.2%.
ELVN Competitors Peer median
Selling, General & Admin for ELVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$1.4B +8.2%+11.2%24.0%
EXELExelixis, Inc.LTM Jul 2026$533.92M +3.0%+4.1%21.9%
RVMDRevolution Medicines, Inc.LTM Jun 2026$328.54M +157.1%+66.4%—
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$176.24M +26.9%+75.5%81.2%
NUVBNuvation Bio Inc.LTM Jun 2026$158.59M +32.6%+68.1%93.3%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$52.28M -5.2%+10.5%—
RLAYRelay Therapeutics, Inc.LTM Jun 2026$51.18M -29.7%-6.5%494.5%
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$36.41M +35.2%+63.3%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$33.29M +12.6%+9.8%—
TYRATyra Biosciences, Inc.LTM Mar 2026$31.48M +21.6%+23.3%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$27.19M +59.1%+55.2%—
Peer median (excluding ELVN) $105.43M+17.1%+17.2%81.2%

Competitors are the stored peer set for ELVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000263K
Gross Profit0000(263K)
Gross Margin—————
Research & Development20.47M31.02M64.57M80.78M85.86M
Selling, General & Admin4.29M7.77M18.96M23.78M33.8M
Operating Expenses24.76M38.79M83.53M104.55M119.4M
Depreciation & Amortization115K215K297K317K263K
EBITDA(24.63M)(37.45M)(71.29M)(88.48M)(103.43M)
EBITDA Margin—————
Operating Income(24.76M)(38.79M)(83.53M)(104.55M)(119.66M)
Operating Margin—————
Interest Income22K1.13M11.97M14.89M16.01M
Interest Expense00000
Other Income / Expenses22K1.13M11.95M15.76M15.96M
Income Before Tax(24.74M)(37.66M)(71.58M)(88.79M)(103.69M)
Pre-Tax Margin—————
Income Tax Expense000232K0
Net Income(24.74M)(37.66M)(71.58M)(89.02M)(103.69M)
Net Margin—————
EPS (Basic)(3.17)(6.03)(2.01)(1.89)(1.83)
EPS (Diluted)(3.17)(6.03)(2.01)(1.89)(1.83)
Weighted Avg Shares7.81M6.25M35.55M47.07M56.66M
Weighted Avg Shares (Diluted)7.82M6.25M35.55M47.07M56.66M

Enliven Therapeutics, Inc.

NASDAQ:ELVN

Intrinsic Alpha fair value

Locked

Current Price

$44.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.